COlchicine in Moderate-severe Hospitalized Patients Before ARDS to Treat COVID-19

PHASE2TerminatedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

April 26, 2020

Primary Completion Date

July 31, 2020

Study Completion Date

July 31, 2020

Conditions
Coronavirus Infection
Interventions
DRUG

Colchicine

People in the colchine group will be given a starting dose of 1.2 mg followed, by 0.6mg after 2 hours if they do not have significant gastrointestinal symptoms, on day 1. After that, they will take colchicine 0.6mg twice a day for 14 days or until discharged or release from the hospital.

DRUG

Usual Care

COVID Patients in this arm will receive usual care COVID19 treatment and will not receive colchine.

Trial Locations (1)

11219

Maimonides Medical Center, Brooklyn

Sponsors
All Listed Sponsors
lead

Maimonides Medical Center

OTHER